1368.4000 -13.40 (-0.97%)
NSE Apr 16, 2025 10:41 AM
Volume: 17,684
 

logo
Eris Lifesciences Ltd.
16 Jun 2017, 12:00AM
1368.40
-0.97%
Systematix Group
Focus on branded prescription based pharmaceutical products catering to lifestyle related disorders: Eris has Develop, Manufacture and Commercialize branded prescription based pharmaceuticals products in select chronic and acute therapeutic areas, like Cardiovascular, Anti-Diabetics, Vitamins, Gastroenterology, Anti-Infectives, & Gynaecology. In FY17, they generated 65.6% of their revenues from the chronic category of the IPM. The chronic category accounted for 34.3% of the IPM in FY17 compared to 31.4% of the IPM in FY13, representing growth at a CAGR of 14.3%. They have identified, developed and are marketing products in the acute category, which are connected to...
Eris Lifesciences Ltd. has an average target of 1379.33 from 3 brokers.
More from Eris Lifesciences Ltd.
Recommended